Detalhe da pesquisa
1.
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Oncologist
; 27(11): 905-e848, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36156099
2.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature
; 515(7528): 563-7, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428504
3.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
; 366(26): 2443-54, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658127
4.
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Cancer Res Commun
; 4(4): 1100-1110, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551394
5.
The application of autologous cancer immunotherapies in the age of memory-NK cells.
Front Immunol
; 14: 1167666, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37205105
6.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
J Thorac Oncol
; 18(8): 1094-1102, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146752
7.
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
J Clin Oncol
; 41(5): 943-954, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750016
8.
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
J Clin Oncol
; 41(4): 715-723, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706735
9.
Microtube device for selectin-mediated capture of viable circulating tumor cells from blood.
Clin Chem
; 58(5): 846-53, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22344286
10.
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288468
11.
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
Clin Cancer Res
; 27(13): 3556-3566, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820780
12.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Cancer Discov
; 10(1): 40-53, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732494
13.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Clin Cancer Res
; 25(20): 6061-6072, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31358540
14.
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
JAMA Oncol
; 5(3): 351-357, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30605211
15.
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
JAMA Oncol
; 5(10): 1411-1420, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31343665
16.
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
J Clin Oncol
; 34(8): 833-42, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755520
17.
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
J Clin Oncol
; 33(18): 2013-20, 2015 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25800770
18.
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 33(18): 2004-12, 2015 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25897158
19.
Differential drug responses of circulating tumor cells within patient blood.
Cancer Lett
; 352(1): 28-35, 2014 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23973263
20.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
J Clin Oncol
; 32(10): 1020-30, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24590637